CDK Inhibitors approved by PBAC 20 April 2018
CDK Inhibitors approved by the Pharmaceutical Benefits Advisory Committee (PBAC) but cost is still an issue. See the link below for further information https://www.bcna.org.au/news/2018/04/cdk-i...
Forum Discussion
I am really disappointed. My onco has told me I am not eligible for Ibrance because it is not the first line treatment for me even though all I have had is 2 aromatose inhibitors and that is during the 5 years I was dx with MBC. He is trying to get it for me on compassionate grounds once again